Abstract
Purpose
This study aimed to determine the diagnostic efficacy of various indicators and models for the prediction of gastric cancer with liver metastasis.
Methods
Clinical and spectral computed tomography (CT) data from 80 patients with gastric adenocarcinoma who underwent surgical resection were retrospectively analyzed. Patients were divided into metastatic and non-metastatic groups based on whether or not to occur liver metastasis, and the region of interest (ROI) was measured manually on each phase iodine map at the largest level of the tumor. Iodine concentration (IC), normalized iodine concentration (nIC), and clinical data of the primary gastric lesions were analyzed. Logistic regression analysis was used to construct the clinical indicator (CI) and clinical indicator-spectral CT iodine concentration (CI-Spectral CT-IC) Models, which contained all of the parameters with statistically significant differences between the groups. Receiver operating characteristic (ROC) curves were constructed to evaluate the accuracy of the models.
Results
The metastatic group showed significantly higher levels of Cancer antigen125 (CA125), carcinoembryonic antigen (CEA), IC, and nIC in the arterial phase, venous phase, and delayed phase than the non-metastatic group (all p < 0.05). Normalized iodine concentration Venous Phase (nICVP) exhibited a favorable performance among all IC and nIC parameters for forecasting gastric cancer with liver metastasis (area under the curve (AUC), 0.846). The combination model of clinical data with significant differences and nICVP showed the best diagnostic accuracy for predicting liver metastasis from gastric cancer, with an AUC of 0.897.
Conclusion
nICVP showed the best diagnostic efficacy for predicting gastric cancer with liver metastasis. Clinical Indicators-normalized ICVP model can improve the prediction accuracy for this condition.
Similar content being viewed by others
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://doi.org/10.3322/caac.21660.
Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–648. https://doi.org/10.1016/S0140-6736(20)31288-5.
Verstegen MH, Harker M, van de Water C, et al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J Gastroenterol. 2020;26(39):6037–6046. https://doi.org/10.3748/wjg.v26.i39.6037.
Milette S, Sicklick JK, Lowy AM, Brodt P. Molecular Pathways: Targeting the Microenvironment of Liver Metastases. Clin Cancer Res. 2017 Jun;23(21):6390–6399. https://doi.org/10.1158/1078-0432.
Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002;235(1):86–91. https://doi.org/10.1097/00000658-200201000-00011.
Marrelli D, Roviello F, De Stefano A, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg. 2004;198(1):51–8. https://doi.org/10.1016/j.jamcollsurg.
Guner A, Son T, Cho I, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016 Jul;19(3): 951–60. https://doi.org/10.1007/s10120-015-0522-z.
Kitakata H, Nemoto-Sasaki Y, Takahashi Y, et al. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 2002;62(22):668–7. PMID: 12438267.
Wen SW, Ager EI, Christophi C. Bimodal role of Kupffer cells during colorectal cancer liver metastasis. Cancer Biol Ther. 2013;14(7):606–13. https://doi.org/10.4161/cbt.24593.
Ham B, Wang N, D’Costa Z, et al. TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases. Cancer Res. 2015;75(24):5235–47. https://doi.org/10.1158/0008-5472.
Song JC, Ding XL, Zhang Y, et al. Prospective and prognostic factors for hepatic metastasis of gastric carcinoma: A retrospective analysis. J Cancer Res Ther. 2019;15(2):298–304. https://doi.org/10.4103/jcrt.
Talebi A, Celis-Morales CA, Borumandnia N, et al.Predicting metastasis in gastric cancer patients: machine learning-based approaches. Sci Rep. 2023;13(1):4163. https://doi.org/10.1038/s41598-023-31272-w.
Tsurumaru D, Nishimuta Y, Muraki T, et al. Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT. Eur J Radiol. 2018 Nov;108: 165–171. https://doi.org/10.1016/j.ejrad.2018.09.030.
Yang H, Sun J, Liu H, et al. Clinico-radiological nomogram for preoperatively predicting post-resection hepatic metastasis in patients with gastric adenocarcinoma. Br J Radiol. 2022 Dec;95(1140):20220488. https://doi.org/10.1259/bjr.20220488.
Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747–795. https://doi.org/10.1002/cac2.12193.
So A, Nicolaou S. Spectral Computed Tomography: Fundamental Principles and Recent Developments. Korean J Radiol. 2021;22(1):86–96. https://doi.org/10.3348/kjr.2020.0144.
Li R, Li J, Wang X, et al. Detection of gastric cancer and its histological type based on iodine concentration in spectral CT. Cancer Imaging. 2018;18(1):42. https://doi.org/10.1186/s40644-018-0176-2.
Zhou Z, Liu Y, Meng K, et al. Application of spectral CT imaging in evaluating lymph node metastasis in patients with gastric cancers: initial findings. Acta Radiol. 2019;60(4):415–424. https://doi.org/10.1177/0284185118786076.
Ren T, Zhang W, Li S, et al. Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer. Diagn Interv Imaging. 2022;103(12):584–593. https://doi.org/10.1016/j.diii.2022.07.004.
Liang P, Ren XC, Gao JB, Chen KS, Xu X. Iodine Concentration in Spectral CT: Assessment of Prognostic Determinants in Patients With Gastric Adenocarcinoma. AJR Am J Roentgenol. 2017;209(5):1033–1038. https://doi.org/10.2214/AJR.16.16895.
Tang L, Li ZY, Li ZW, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70(11):1198–204. https://doi.org/10.1016/j.crad.2015.06.083.
Liu J, Chai Y, Blinded for anonymity, et al. Spectral Computed Tomography Imaging of Gastric Schwannoma and Gastric Stromal Tumor. J Comput Assist Tomogr. 2017 May/Jun;41(3):417–421. https://doi.org/10.1097/RCT.0000000000000548.
Chen XH, Ren K, Liang P, et al. Spectral computed tomography in advanced gastric cancer: Can iodine concentration non-invasively assess angiogenesis?. World J Gastroenterol. 2017;23(9):1666–1675. https://doi.org/10.3748/wjg.v23.i9.1666.
Greffier J, Hamard A, Pereira F, et al. Image quality and dose reduction opportunity of deep learning image reconstruction algorithm for CT: a phantom study. 2020;30(7):3951–3959. https://doi.org/10.1007/s00330-020-06724-w.
Dabli D, Frandon J, Belaouni A, et al. Optimization of image quality and accuracy of low iodine concentration quantification as function of dose level and reconstruction algorithm for abdominal imaging using dual-source CT: A phantom study. Diagn Interv Imaging. 2022;103(1):31–40. https://doi.org/10.1016/j.diii.2021.08.004.
Benchoufi M, Matzner-Lober E, Molinari N, et al. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101(10):639–641. https://doi.org/10.1016/j.diii.2020.09.001.
Gong W, Su Y, Liu A, et al. Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma. Neoplasma. 2018;65(3):326–330. https://doi.org/10.4149/neo2018_170.
Dochez V, Caillon H, Vaucel E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. https//doi:10.1186/s 13048-019-0503-7.
Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190–8. https://doi.org/10.1074/jbc.M312372200.
Chen SH, Hung WC, Wang P, et al. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013 May;3:1870. https://doi.org/10.1038/srep01870.
Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006 Oct;26;5(1):50. https://doi.org/10.1186/1476-4598-5-50.
Lee JH, Lee SW. The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches. Gastroenterol Res Pract. 2017 May;2017:7521987. https://doi.org/10.1155/2017/7521987.
Kim CW, Roh SA, Tak KH, et al. ZKSCAN3 Facilitates Liver Metastasis of Colorectal Cancer Associated with CEA-expressing Tumor. Anticancer Res. 2016 May;36(5): 2397–2406. PMID: 27127149.
Wang W, Chen XL, Zhao SY, et al. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. Oncotarget. 2016;7(23):35423–36https://doi.org/10.18632/onco-.
Li R, Li J, Wang X, et al. Detection of gastric cancer and its histological type based on iodine concentration in spectral CT. Cancer Imaging. 2018;18(1):42https://doi.org/10.1186/s40644-018-0176-2.
Hong WG, Ko YS, Pyo JS. Clinicopathological significance and prognostic role of microvessel density in gastric cancer: A meta-analysis. Pathol Res Pract. 2017;213(12):1459–1463. https://doi.org/10.1016/j.prp.2017.11.001.
Liu Y, Cui H, Xu X, et al. Prognostic value of lymph node density on cancer staging system for gastric cancer without distal metastasis: a population-based analysis of SEER database. World J Surg Oncol. 2022;20(1):325. https://doi.org/10.1186/s12957-022-02795-9.
You MW, Park S, Kang HJ, et al. Radiologic serosal invasion sign as a new criterion of T4a gastric cancer on computed tomography: diagnostic performance and prognostic significance in patients with advanced gastric cancer. Abdom Radiol (NY). 2020;45(10):2950–2959. https://doi.org/10.1007/s00261-019-02156-3.
Funding
This work was supported by the National Natural Science Foundation of China (82102151). Lanzhou Youth Science and Technology Talent Innovation Project (2023-2-44); Lanzhou University Second Hospital Cuiying Project (CY2023-QN-B09).
Author information
Authors and Affiliations
Contributions
Yingxia She: Conceptualization, Methodology, Data Curation, Writing - original draft. Xianwang Liu: Statistical analysis, Resources, Original draft, Revision. Hong Liu: Methodology, Revision. Haiting Yang: Resources, Revision, Funding acquisition. Wenjuan Zhang: Revision, Funding acquisition. Yinping Han: Resources, Revision. Junlin Zhou: Conceptualization, Methodology, Supervision, Funding acquisition.
Corresponding author
Ethics declarations
Informed consent
The study was approved by the Institutional Review Board, and informed consent was waived due to retrospective analysis of the study.
Conflict of interest
All authors have no conflicts of interest to declare.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
She, Y., Liu, X., Liu, H. et al. Combination of clinical and spectral-CT iodine concentration for predicting liver metastasis in gastric cancer: a preliminary study. Abdom Radiol (2024). https://doi.org/10.1007/s00261-024-04346-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00261-024-04346-0